Tysabri Screening Test May Be Unreliable
By John Gever, Deputy Managing Editor, MedPage Today Published: June 05, 2013 Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of…
PML Not Fatal if Caught Early
By John Gever, Senior Editor, MedPage Today Published: March 11, 2013 Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of…
Stuart Schlossman
Natalizumab shows promise for teens with multiple sclerosis
February 22, 2013 in Neuroscience (HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according…
Stuart Schlossman
MS Patient Dies from Anti-Drug Antibodies
This report is part of a 12-month Clinical Context series. By John Gever, Senior Editor, MedPage Today Published: February 10, 2013…
Stuart Schlossman
BIOGEN IDEC AND ELAN SUBMIT APPLICATIONS FOR FIRST-LINE USE OF TYSABRI IN ANTI-JCV ANTIBODY NEGATIVE PATIENTS WITH MS
– Marketing Applications Supported by Risk Stratification Data – WESTON, Mass. & DUBLIN–(BUSINESS WIRE)–Jan. 16, 2013– Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE:…
Stuart Schlossman
Investigators Recruiting for Study of Tysabri in Early Relapsing-Remitting MS
Aug 24, 2012 Summary: U.S. investigators are recruiting 300 people with early relapsing-remitting MSto detect factors that might help better predict which…
Stuart Schlossman
Health Canada approves Biogen Tysabri label change
May 24, 2012 Health Canada has approved a change to the TYSABRI Product Monograph to assist physicians and patients with…
Stuart Schlossman
New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine
18 May 2012 – Use of Biomarker has Potential to Advance Personalized Treatment for MS Patients – WESTON, MA, USA…
Stuart Schlossman
Tysabri Seems OK for Expectant Mothers with MS
By Ed Susman, Contributing Writer, MedPage Today Published: April 29, 2012 Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of…
Stuart Schlossman
New TYSABRI Data Presented at 64th Annual AAN Meeting Highlight Biogen Idec & Elan Commitment to Improving Outcomes in Multiple Sclerosis
Published April 27, 2012 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced findings from several studies of TYSABRI® (natalizumab)…
Stuart Schlossman
